Global Community
Our community narratives are driven by numbers and valuation.
Community Investing Ideas
Global Weekly Picks
Saudi Telecom set to evolve into a digital powerhouse with strong government backing
In the next 5 years , STC (Saudi Telecom Company) is likely to evolve into a leading regional digital powerhouse with a strong presence in telecommunications, technology, and digital services. Here’s why: 1.Read more
Accenture's Revenue to Climb 5% with a Promising 11% Profit Margin Boost
Fundamental 1) Valuation & Quality Multiples: TTM P/E ~20.3x , Forward P/E ~18.1x , EV/EBITDA ~13.3x , P/S ~2.36x , P/B ~5.21x (all trending well below 2024 peaks). Scale & Efficiency: Revenue (TTM) ~US$68.5B , Operating margin ~16.8% , Net margin ~11.6% , ROE ~26.9%.Read more
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.Read more
The Architect of Integrated, High-Performance Security
When compared to other competitors, Fortinet's valuation makes a lot of sense. Fortinet is a model of profitability and operational efficiency.Read more
Bonava will at least triple its market value when the housing market recovers
If earnings hit half of what they were when the company founded in 2016, which was a reasonable housing market period, the company will profit around half a billion SEK. With a P/E multiple of 14, that is around 7 billion sek, which is 3 times the current market value.Read more
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.Read more
Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition
Duopharma Biotech Bhd (KLSE: DPHARMA, ticker 7148) Healthcare – Pharmaceuticals / Biotech Investment Review Recommendation: HOLD (Initiated) Key Metrics Company Overview Duopharma Biotech Bhd is a leading pharmaceutical manufacturer in Malaysia, involved in the research, development, manufacturing, and distribution of generic and specialty pharmaceutical products. Its operations span: Ethical Classic : General therapeutic generics (e.g., cardiovascular, anti-infectives) Ethical Specialty : Bio-similars for oncology, renal, and metabolic diseases Consumer Healthcare (CHC) : Notable OTC brands like Champs, Flavettes, and Uphamol As of 2025, it exports to multiple countries and operates from 3 GMP-certified manufacturing facilities.Read more
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.Read more
BMO Nasdaq 100 ETF will see a 27.2% boost in profit margins over 5 years
The investment strategy as stated in the fund's prospectus is: BMO Nasdaq 100 Equity Index ETF seeks to replicate, to the extent possible, the performance of a NASDAQ listed companies index, net of expenses. Currently, and BMO Nasdaq 100 Equity Index ETF seeks to replicate the performance of the NASDAQ-100 Index.Read more
